2006
Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, REILLY RF. Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders. Nephrology 2006, 11: 142-146. PMID: 16669977, DOI: 10.1111/j.1440-1797.2006.00544.x.Peer-Reviewed Original ResearchConceptsCalcium-containing bindersSerum phosphorus concentrationLower serum bicarbonate concentrationEnd-stage renal diseaseCalcium-phosphorus productSerum bicarbonate concentrationSevelamer hydrochloridePhosphate bindersCalcium-containing phosphate bindersElevated calcium-phosphorus productHigher serum phosphorus concentrationsMmol2/L2Retrospective chart reviewLong-term efficacyCa-P productLong-term comparative studiesBicarbonate concentrationESRD patientsChart reviewRenal diseaseCalcium loadPatientsLong-term comparisonTarget goalsEfficacy
2004
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal Of Medicine 2004, 350: 1516-1525. PMID: 15071126, DOI: 10.1056/nejmoa031633.Peer-Reviewed Original ResearchConceptsParathyroid hormone levelsPrimary end pointSecondary hyperparathyroidismHormone levelsPlacebo groupCinacalcet groupLow parathyroid hormone levelsSerum calcium-phosphorus productIntact parathyroid hormone levelsEnd pointCalcium-phosphorus productEfficacy assessment phaseParathyroid hormone valuesPatients Receiving HemodialysisPlacebo-controlled trialPercentage of patientsAdverse clinical outcomesCalcium-phosphorus homeostasisCalcium-sensing receptorClinical outcomesVitamin DDaily dosesStandard treatmentHormone valuesCardiovascular disease